1. Egypt Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda

EEGX:RMDA
5.00
EGP
-0.16
(-3.10%)
0.18EPS
28.10P/E
10.06BMarket Cap
Dec 02Next Earn
Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda
EGX:RMDA
(Egyptian Exchange)

Recent

price

5.00

P/E

ratio

28.10

div

yld

1.70%

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
EGP
0.4
0.44
0.48
0.62
0.76
0.97
1.38
2.05
2.34
Revenue per Share
0.06
0.04
0.06
0.09
0.13
0.12
0.19
0.15
0.18
Basic EPS, GAAP
-0.12
-0.02
-0.18
- -
-0.05
-0.15
-0.19
-0.4
0.02
Free Cash Flow per Basic Share
- -
- -
- -
0.01
0.01
0.01
0.06
0.09
0.09
Dividend per Share
0.23
0.53
0.59
0.67
0.78
0.89
1.03
1.08
1.15
Book Value per Share
0.18
0.48
0.48
0.48
0.54
0.59
0.75
0.53
0.61
Tangible Book Value per Share
2,015
2,015
2,015
2,015
1,952
1,973
2,002
2,000
1,878
Basic Weighted Avg Shares
806
894
960
1,246
1,484
1,922
2,769
4,096
4,388
Sales/Revenue/Turnover
30.78
23.93
19.11
21.59
22.63
22.7
25.25
25.51
24.28
Operating Margin (%)
25
36
56
46
65
73
83
92
89
Depreciation Expense
129
82
112
181
246
245
387
298
331
Net Income, GAAP
22.95
23.8
23.15
22.91
23.01
22.67
23.63
26.15
27.54
Effective Tax Rate (%)
16.02
9.22
11.68
14.53
16.56
12.74
13.99
7.29
7.54
Profit Margin (%)
-41
572
506
454
577
650
982
451
644
Working Capital
- -
62
44
12
16
12
7
75
75
LT Debt
472
1,072
1,184
1,345
1,523
1,775
2,072
2,210
2,374
Total Equity
- -
11.77
7.54
9.7
11.82
13.34
17.4
19.4
18.56
Return on Invested Capital (%)
- -
11.97
9.91
11.74
13.2
14.5
18.86
16.6
15.82
Return on Capital (%)
- -
10.66
9.94
14.3
17.14
14.93
20.35
14.17
15.18
Return on Common Equity (%)

Capital Structure

EGP

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,268
2,159
2,279
LT Borrowings
- -
- -
- -
LT Finance Leases
75
72
75
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,000
2,000
2,033
Market Capitalization
6,660
8,120
10,062

Working Capital

EGP

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,435
3,409
3,751
Cash, Cash Equivalents & STI
36
44
105
Accounts Receivable, Net
1,027
1,073
972
Inventories
1,125
855
1,011
Total Current Liabilities
2,984
2,904
3,107
Payables & Accruals
- -
- -
- -
ST Debt
2,268
2,159
2,279
Deferred Revenue
- -
- -
- -

Growth Rates

EGP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.36%
6.67%
Free Cash Flow
- -
-600.25%
112.69%
Net Income, GAAP
- -
26.4%
-22.95%
Sales/Revenue/Turnover
- -
34.08%
47.94%
Total Cash Common Dividend
- -
- -
55.77%

Quarterly Revenue

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
456
565
763
984
2,769
2025
866
963
1,135
1,132
4,096
2026
1,067
1,054
- -
- -
- -

Quarterly Earnings Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.06
0.08
0.19
2025
0.04
0.04
0.05
0.02
0.15
2026
0.05
0.05
- -
- -
- -

Quarterly Dividends Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.04
0.06
2025
- -
- -
0.04
0.05
0.09
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tenth of Ramadan Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. is an Egypt-based pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of generic prescription medicines, consumer healthcare formulations, veterinary pharmaceuticals, and diagnostic reagents. Founded in 1986 and headquartered in Giza, Egypt, the company operates manufacturing facilities in 6th of October City. Rameda organizes its operations across a broad spectrum of therapeutic areas, offering systemic anti-infectives and antibiotics; alimentary tract and gastrointestinal medications; cardiovascular and antihypertensive drugs; central nervous system agents and analgesics; respiratory and antihistamine treatments; musculoskeletal and anti-inflammatory therapies; genitourinary and hormonal preparations; ophthalmic medications; and dietary supplements, nutraceuticals, and vitamins. The company also provides comprehensive contract and toll manufacturing services to regional and multinational pharmaceutical enterprises. While maintaining a strong market presence across domestic retail pharmacies and public healthcare institutions in Egypt, Rameda exports its products across the Middle East and Africa, including Iraq, Yemen, Libya, Sudan, and selected Gulf Cooperation Council (GCC) member states. In recent strategic developments, Rameda has pursued aggressive portfolio diversification through the acquisition and in-licensing of high-margin molecules and branded generic products, notably across chronic disease management, cardiology, ophthalmology, and specialty consumer health. The company has expanded its manufacturing capacity and upgraded production lines to support growing export volumes, launched new chronic therapy formulations, and strengthened regional distribution partnerships to accelerate foreign-currency revenue generation.